Navigation Links
Insmed to Seek Shareholder Approval for Reverse Split
Date:10/14/2008

RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it will seek shareholder approval to implement a reverse stock split, if necessary, at a Special Meeting of Stockholders on November 24, 2008, in an effort to meet the minimum bid price rule for continued listing on The NASDAQ Stock Market.

On September 3, 2008, the Company announced that the NASDAQ Listing Qualifications Panel had granted Insmed's request to remain listed on The NASDAQ Stock Market, subject to the condition that on or before December 15, 2008, Insmed must evidence a closing bid price of $1.00 or more for a minimum of ten consecutive business days (the "Minimum Bid"). The process for formally seeking shareholder approval for a reverse split takes several weeks and, therefore, needs to be initiated at this time so that it can be in place, if needed, to meet the December 15, 2008 compliance deadline. If Insmed is able to attain the Minimum Bid by the compliance deadline without the need for a reverse stock split, the Company may choose not to effect the split.

"Insmed, in conjunction with RBC Capital Markets, continues to work diligently to secure an appropriate partner for our follow-on biologics business," said Geoffrey Allan, President and CEO of Insmed. "Given that we are not able to determine the exact timing and potential impact of a partnership on our share price at this time, we felt it was prudent to take the necessary steps to enable us to execute a reverse split, should we need to, in order to maintain our listing on NASDAQ. Given the current economic climate, we believe being a NASDAQ-listed company and having access to the capital markets is necessary."

The date for determining stockholders of record entitled to receive notice of, and to vote at, the Special Meeting is October 17, 2008. A definitive proxy statement containing important stockholder inform
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... NEWTOWN, Pa. , June 2, 2015   ... services and technology provider, today announced that David ... has been named Executive Vice President and Chief Financial ... 8, 2015. Peters brings more than 25 ... in pharmaceutical services. "David has extensive and deep knowledge ...
(Date:6/2/2015)... , June 2, 2015  Alere Inc. ... rapid diagnostics, joined the White House Antibiotic Stewardship ... commitments to support and advance the President,s National ... commitments include a number of measurable goals and ... achieved, will help healthcare providers protect their patients ...
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
Breaking Biology Technology:BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... BIOD ) today reported financial results for the ... Quarter Operating Highlights During Biodel,s third quarter of ... 1 testing of two new ultra-rapid-acting formulations of recombinant human ... at Oregon Health and Sciences University who have initiated a ...
... Calif. and TORONTO, Aug. 4, 2011 ... developing a first-in-class anti-apoptosis therapeutic protein known as ... www.generex.com ), a biotechnology company developing a buccal ... in a Phase III trial, today are making ...
... AMSTERDAM, The Netherlands, August 4, 2011 SynCo ... of biopharmaceuticals today announced that its aseptic filling facility is ... first drug product batches for its clients after the expansion ... of the Class A zone is an important milestone in ...
Cached Biology Technology:Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 6Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 2Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 3Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 4Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 5SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Boulder, Colo., USA New GSA Bulletin articles cover wind ... on Kauai; new insights from the Petrified Forest, USA; a ... a new model for the development of Ries Crater Lake, ... large earthquakes in northern Fiordland, New Zealand; and the evolution ...
... research at the Institute of Food Research, has taken ... and drug companies worldwide. , IFR and the technology ... from the Biotechnology and Biological Sciences Research Council (BBSRC) ... and improve how well it simulates the release of ...
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
Cached Biology News:Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 2Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 3Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 4Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 5Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 6Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 7Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 8Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 9Commercial future for Model Gut 2Cell discovery could hold key to causes of inherited diseases 2
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
100 adhesive strips....
Request Info...
Biology Products: